GlassScriptPhysician profile
Devon James Zafuto
NPI 1497497150
$5,592.63
in general payments reported to CMS, 2019-2025
23 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $741 · 2023: $1,245 · 2024: $2,255 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.42 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $715.45 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $661.20 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $610.62 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $570.29 | 2022-2025 | Fanapt, Hetlioz, Ponvory |
| Janssen Pharmaceuticals, INC | $542.93 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $526.86 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.26 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $379.38 | 2022-2025 | Ingrezza |
| Corium, LLC | $295.88 | 2022-2024 | Azstarys |
| Lundbeck LLC | $251.76 | 2024-2025 | Rexulti |
| Uswm, LLC | $98.90 | 2022-2023 | Lucemyra, Zimhi |
| Bausch Health US, LLC | $95.29 | 2024-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $89.02 | 2024 | Auvelity |
| Almatica Pharma LLC | $70.34 | 2022-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $59.19 | 2022-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $44.52 | 2023-2024 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $40.25 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $30.60 | 2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.20 | 2023 | Relistor |
| Collegium Pharmaceutical, INC. | $18.92 | 2025 | Jornay Pm |
| Biogen, INC. | $17.99 | 2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $16.85 | 2023 | Jornay Pm |
| Tris Pharma INC | $15.93 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Zafuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.